BioNTech (BNTX) Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Do institutionals & insiders believe in GSK or BNTX?

15.7% of GSK shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate GSK or BNTX?

GSK presently has a consensus price target of $37.38, indicating a potential downside of 2.19%. BioNTech has a consensus price target of $137.86, indicating a potential upside of 25.27%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.10
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83

Does the media refer more to GSK or BNTX?

In the previous week, GSK had 13 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for GSK and 2 mentions for BioNTech. GSK's average media sentiment score of 0.87 beat BioNTech's score of 0.47 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, GSK or BNTX?

GSK has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Which has higher valuation & earnings, GSK or BNTX?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$40.10B	1.95	$3.29B	$1.94	19.70
BioNTech	$2.98B	8.89	-$719.92M	-$3.40	-32.37

Is GSK or BNTX more profitable?

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	9.89%	48.82%	11.15%
BioNTech	-27.37%	-3.94%	-3.41%

Summary

GSK beats BioNTech on 10 of the 16 factors compared between the two stocks.